Erik Johan Eliasson

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Erik Eliasson är professor i farmakogenetik vid institutionen för laboratoriemedicin, avdelningen för klinisk farmakologi. Klinisk farmakologi handlar om att utveckla rationell läkemedelsbehandling och prediktiva test för vilka som riskerar biverkningar eller att svara dåligt på en behandling. Inom forskningen i farmakogenetik fokuserar man på genetiska förklaringar till biverkningar respektive dåligt behandlingssvar.

Erik Eliasson är vid sidan av sin professur även överläkare på farmakologiska laboratoriet vid Karolinska Universitetssjukhuset.

Artiklar

Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2026;81(5):dkag116
Optimizing cloxacillin prophylaxis in hip and knee arthroplasty based on population pharmacokinetics of unbound plasma concentrations
Beijer G; Wallander K; Soderquist B; Giske CG; Breuer O; Eriksen J; Eliasson E
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2026;81(3):dkag067
Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort
Wallander K; Beijer G; Eliasson E; Giske CG; Ponzer S; Soderquist B; Eriksen J
Article: ACTA ONCOLOGICA. 2025;64:848-856
CYP2D6 genotype and outcome in tamoxifen treated early breast cancer
Thoren L; Lindh JD; Molden E; Kringen MK; Bergh J; Eliasson E; Margolin S
Article: CRITICAL CARE. 2025;29(1):208
First dose target attainment with extended infusion regimens of piperacillin and meropenem
Beijer G; Swartling M; Nielsen EI; Breuer O; Giske CG; Eliasson E; Petersson J
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025;117(4):629-636
Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial
Hammarstrom M; Gabrielson M; Bergqvist J; Lundholm C; Crippa A; Backlund M; Wengstrom Y; Borgquist S; Eliasson E; Eriksson M; Tapia J; Czene K; Hall P
Article: NUCLEIC ACIDS RESEARCH. 2025;53(D1):D1498-D1509
PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes
Tremmel R; Zhou Y; Camara MD; Laarif S; Eliasson E; Lauschke VM
Article: BREAST CANCER RESEARCH AND TREATMENT. 2023;198(3):499-508
Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records
Thoren L; Margolin S; Eliasson E; Bergh J; Lindh JD
Article: HUMAN GENOMICS. 2023;17(1):15
Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences
Zhou Y; Nevosadova L; Eliasson E; Lauschke VMM
Article: THERAPEUTIC DRUG MONITORING. 2023;45(1):45-54
Reproducible Quantification of Unbound Fractions of Four Beta-Lactam Antibiotics: Ultrafiltration Versus Microdialysis of Spiked Healthy Donor Plasma
Beijer G; Clarin L; oestervall J; Barclay V; Eliasson E
Article: SCIENTIFIC REPORTS. 2022;12(1):21891
Low attainment to PK/PD-targets for β-lactams in a multi-center study on the first 72 h of treatment in ICU patients
Smekal A-K; Furebring M; Eliasson E; Lipcsey M
Article: BREAST CANCER RESEARCH AND TREATMENT. 2021;190(3):451-462
Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
Thoren L; Eriksson M; Lindh JD; Czene K; Bergh J; Eliasson E; Hall P; Margolin S
Article: ANNALS OF ONCOLOGY. 2021;32(10):1286-1293
CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial
He W; Eriksson M; Eliasson E; Grassmann F; Backlund M; Gabrielson M; Hammarstrom M; Margolin S; Thoren L; Wengstrom Y; Borgquist S; Hall P; Czene K
Article: LAKARTIDNINGEN. 2021;118:20176
[Pharmacogenomics - a cornerstone of Precision Medicine. Genomic Medicine Sweden analyses genotypes associated with serious drug toxicity or therapeutic failure].
Eliasson E; Wadelius M
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2021;65(4):e02029-e02020
Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy
Petersson J; Giske CG; Eliasson E
Article: EUROPEAN RESPIRATORY JOURNAL. 2021;57(3):2003463
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
Davies Forsman L; Niward K; Kuhlin J; Zheng X; Zheng R; Ke R; Hong C; Werngren J; Paues J; Simonsson USH; Eliasson E; Hoffner S; Xu B; Alffenaar J-W; Schön T; Hu Y; Bruchfeld J
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2021;77(3):409-419
Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients
Holm J; Mannheimer B; Malmstrom RE; Eliasson E; Lindh JD
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2021;87(3):1243-1252
Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles
Thoren L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
Article: PHARMACOGENOMICS JOURNAL. 2020;20(4):579-585
SWEDEGENE-a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions
Hallberg P; Yue Q-Y; Eliasson E; Melhus H; As J; Wadelius M
Journal article: THERAPEUTIC DRUG MONITORING. 2020;42(3):353
In Memoriam: Professor Folke Sjoqvist
Christians U; Henthorn TK; Walson PD; Oellerich M; Eliasson E
Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(6):548-557
CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
He W; Grassmann F; Eriksson M; Eliasson E; Margolin S; Thoren L; Hall P; Czene K
Visa fler

Alla övriga publikationer

Study protocol: BMJ OPEN. 2026;16(4):e109745
Unbound cloxacillin plasma concentrations in relation to toxicity and renal function: protocol for a prospective, observational clinical trial in a real-world Staphylococcus aureus bacteraemia population
Damgaard T; Hellborg T; Larsson A; Eliasson E; Bonnedahl J; Nielsen EI; Schon T; Hallgren A
Review: ANALYTICAL AND BIOANALYTICAL CHEMISTRY. 2024;416(26):5565-5577
Development and clinical implementation of an LC-HRMS method for ivacaftor, lumacaftor, tezacaftor and elexacaftor in human plasma and breast milk.
Hansson AB; Wadström H; Eliasson E; Al Shakirchi M; de Monestrol I; Barclay V
Letter: LAKARTIDNINGEN. 2024;121:151
Nya rekommendationer för infusion av betalaktamantibiotika.
Gustafsson T; Eliasson E; Furebring M; Nielsen E; Petersson J; von Seth M; Tängden T
Review: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2022;131(6):452-464
A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing
Zhou Y; Koutsilieri S; Eliasson E; Lauschke VM
Other: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;108(6):1127-1128
Tribute to Folke Sjoqvist, a Pioneer in Clinical Pharmacology
Dahl M-L; Bergman U; Bertilsson L; Eliasson E; Gustafsson LL; Panagiotidis G; Rane A
Study protocol: BMJ OPEN. 2018;8(9):e023899
Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study
Forsman LD; Niward K; Hu Y; Zheng R; Zheng X; Ke R; Cai W; Hong C; Li Y; Gao Y; Werngren J; Paues J; Kuhlin J; Simonsson USH; Eliasson E; Alffenaar J-W; Mansjo M; Hoffner S; Xu B; Schon T; Bruchfeld J
Letter: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2017;121(4):215-216
Reply to "Multiple and Opposite Effects of Angiotensin II Receptor Blockers on the Bioavailability of Epoxyeicosatrienoic Acids'
Senda A; Mukai Y; Hayakawa T; Kato Y; Eliasson E; Rane A; Toda T; Inotsume N
Review: LAKARTIDNINGEN. 2015;112:CW3P
[Beta lactam antibiotics and the question of dose regimen for severe infection. Prolonged infusion theoretically appealing--yet no evidence of clinical benefit].
Leander G; Eliasson E; Hanberger H; Giske C
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2013;45(3):161-175
Rational use of aminoglycosides-Review and recommendations by the Swedish Reference Group for Antibiotics (SRGA)
Hanberger H; Edlund C; Furebring M; Giske CG; Melhus A; Nilsson LE; Petersson J; Sjolin J; Ternhag A; Werner M; Eliasson E
Editorial: PHARMACOGENOMICS. 2012;13(16):1887-1891
Karolinska Institutet
Eliasson E; Sim SC; Rane A; Ingelman-Sundberg M
Letter: PHARMACOGENOMICS. 2012;13(14):1561-1562
Influence of the CYP2C9*3 allele on the pharmacological interaction between warfarin and simvastatin: author reply
Andersson ML; Eliasson E; Lindh JD
Review: JOURNAL OF INTERNAL MEDICINE. 2010;268(6):540-548
Drug-drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice
Mannheimer B; Eliasson E
Letter: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2009;65(10):1055
Severely diminished response to vitamin K-treatment for self-inflicted warfarin intoxication in a patient genotyped as CYP2C9*3*3
Backstrom T; Barkman G; Lindh JD; Eliasson E
Published conference paper: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2007;81(6):899-902
The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine:: Focus on antidepressants
Sjoqvist F; Eliasson E
Letter: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2006;80(3):301-302
Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele? Reply
Eliasson E; Lundblad MS
Editorial: BMJ-BRITISH MEDICAL JOURNAL. 2006;332(7551):1163-1164
Ethnicity and adverse drug reactions - Personalised drug treatment is getting closer but will not replace good clinical judgment
Eliasson E
Letter: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2006;79(3):287-288
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3
Lundblad MS; Ohlsson S; Johansson P; Lafolie P; Eliasson E
Published conference paper: DRUG METABOLISM AND DISPOSITION. 2004;32(5):484-489
The impact of CYP2C9 genetics and oral contraceptives on cytochrome P4502C9 phenotype
Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
Review: DRUG METABOLISM AND DISPOSITION. 2002;30(10):1053-1058
Reactive intermediates and the dynamics of glutathione transferases
Rinaldi R; Eliasson E; Swedmark S; Morgenstern R
Letter: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2002;54(2):183-185
Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity
Yasar Ü; Dahl ML; Christensen M; Eliasson E
Visa fler

Anställningar

Professor/Överläkare, Farmakogenetik, Laboratoriemedicin, Karolinska Institutet, 2012-

Examina och utbildning

Docent, Klinisk farmakologi, Karolinska Institutet, 2000
Läkarexamen, Karolinska Institutet, 1994

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI